According to its Q2FY26 business update, the growth at the consolidated level was led by robust momentum in preventive health check-ups through its TruHealth and wellness offerings.
Despite a lower incidence of seasonal diseases such as dengue, malaria and viral fever compared to the previous year, the company delivered solid performance, reflecting the strength of its diversified portfolio and alignment with growing demand for proactive health and well-being.
The 23% YoY revenue growth includes contributions from recently acquired Core Diagnostics, Scientific Pathology in Agra, and Dr. Ahuja’s Pathology & Imaging Center (DAPIC) in Dehradun.
Core Diagnostics has moved from breakeven in Q4FY25 to a low single-digit positive margin in Q1FY26, and further improved to a high single-digit margin in Q2FY26. The company attributed this to ongoing improvements in operational efficiency, synergies, and operating leverage.
DAPIC and Scientific Pathology continued to outperform the company’s average margin performance, further boosting profitability.Metropolis reported that its TruHealth Wellness and Specialty segments grew approximately 25% and 36% YoY, respectively, during the quarter. Its B2C business posted 16% YoY growth, while the B2B segment, largely driven by Core Diagnostics, jumped by about 34%.The company also highlighted its strong balance sheet, remaining debt-free with a net cash surplus of around Rs 55 crore.
The quarter also saw the company expand its footprint through the acquisition of Dr. RS Patil’s Ambika Pathology Laboratory in Kolhapur, effective September 18, 2025. The move is expected to strengthen its leadership in the region and help establish a mini reference lab to serve surrounding districts in Western Maharashtra by enhancing productivity and turnaround time.
On a standalone basis, the company posted a 12% YoY revenue growth driven by increased test volumes, improved realizations, and a favourable shift in product mix. EBITDA margins improved both sequentially and annually, reflecting the strong operating leverage inherent in the business.
Also read: The dreaded Rs 10,000-crore IPO curse may be breaking. Can LG and Tata Capital seal the turnaround?
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
as a Reliable and Trusted News Source